Anastrozole and tamoxifen yield similar disease recurrence outcomes in postmenopausal women with ductal carcinoma in situ (DCIS), but side-effect profiles of the two vary, making anastrozole suitable for women with contraindications to tamoxifen, the phase III IBIS-II DCIS (International Breast Cancer Intervention-II DCIS) trial has shown.
Adjuvant capecitabine therapy significantly improved disease-free survival (DFS) in HER2-negative primary breast cancer patients with residual invasive disease after neoadjuvant chemotherapy (NAC), according to results of the CREATE-X* trial presented at the recent San Antonio Breast Cancer Symposium 2015 in San Antonio, Texas, US.
Adjuvant treatment with a low dose of denosumab decreased the risk of fractures and improved disease-free survival (DFS) in postmenopausal women with early, HR-positive breast cancer, when added to aromatase inhibitor (AI) therapy.
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.